News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Visterra Inks First Antibody Deal, With Pfizer Inc. (PFE)


9/11/2012 7:28:09 AM

Pfizer and Visterra inked a collaboration agreement focused on the discovery of therapeutic antibodies based on the latter’s platform for the identification of drug target sites and drug design. Under terms of the deal, which represents Visterra’s first pharmaceutical partnership, the firm will receive an up-front fee and research funding, plus research and development milestones and future sales royalties. “This collaboration further supports the potential utility of Visterra’s antibody design platform, and we look forward to collaborating with Pfizer while we continue to advance Visterra’s own internal product pipeline,” comments Visterra CEO Steven Brugger.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES